← Back to Search

Unknown

QLS-101 for Normal Tension Glaucoma

Phase 2
Waitlist Available
Research Sponsored by Qlaris Bio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ability to washout from current intraocular pressure lowering medications -
Visual acuity +1.0 logMAR or better
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 86 days
Awards & highlights

Study Summary

This study is evaluating whether a new drug called QLS-101 is safe and tolerable for people with normal tension glaucoma.

Eligible Conditions
  • Normal Tension Glaucoma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~86 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 86 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Ocular safety
Secondary outcome measures
Ocular hypotensive efficacy

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: QLS-101 ophthalmic solution 2.0%Experimental Treatment1 Intervention
Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
Group II: QLS-101 ophthalmic solution 1.0%Experimental Treatment1 Intervention
Ophthalmic solution once daily (QD) dosing in both eyes (OU) for 14 days followed by 14 days of twice daily (BID) dosing.
Group III: Timolol maleate PF 0.5% ophthalmic solutionActive Control2 Interventions
Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
QLS-101
2021
Completed Phase 2
~120

Find a Location

Who is running the clinical trial?

Qlaris Bio, Inc.Lead Sponsor
6 Previous Clinical Trials
317 Total Patients Enrolled
Qlaris BioStudy ChairWellesley, MA
B. Wirostko, M.D.Study DirectorQlaris Bio, Inc.
1 Previous Clinical Trials
3 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~9 spots leftby Mar 2025